About Us

At Hoba Therapeutics we are a dedicated team with world-class expertise in pain and development of biopharmaceuticals.

 

Our goal is to improve pain treatment with novel and innovative drugs

Vision & Mission

 

Hoba Therapeutics vision is to become the leading company developing biopharmaceuticals for the treatment of neuropathic pain

 

Our mission is to provide innovative effective, safe and disease modifying treatments to patients living with neuropathic pain

  • Consce magna aliqua.
  • Veniam quis nostrus.
  • Borisns con repehner.
  • Veles cillueu excpars.
  • Snculpa in mollianime.
  • Perscatis omn natus.

 

OUR MANAGEMENT

 

Hoba Therapeutics is a Danish biotech company with an experienced leadership and Board of Directors

 

 

KENNETH PETERSEN, MD, PhD

CEO

  • Previously, Chief Specialist Business development H.Lundbeck
  • >12 years of pharma experience (NatImmune, Novo Nordisk and Lundbeck) with positions in clinical- and business development with special focus on pain drugs
  • >8 years of clinical experience in internal medicine, pediatrics and neurology
  • PhD thesis based on preclinical and clinical research in migraine headache (>20 publications)

 

 

OUR BOARD

LENE GERLACH, MSc, PhD

Board member (Borean Innovation):

 

  • Portfolio manager Borean Innovation
  • Chairman in Adapa, My Digital Life, Paqle and Cathvision, Board Member in Northern VO
  • Former Chairman in Eye-Go, Amphidex, Advanced Substrate Techologies, NerveX and Straxfix; former Board Member in Decumed and Suma Care
  • Former VP in the biotech company Action Pharma and the IT-company Visiopharm
  • 10 years of experience from the biotech and software industry with special knowledge within IP, business development and sales

 

 

 

AMANDA L HAYWARD, BSc, PhD

Chairman

  • Independent strategic consultant to entrepreneurs, companies and venture funds, Venture Partner, Connecticut Innovations
  • Experienced Board, BD, Startup operations and venture investment executive
  • Previously, Partner Baxalta Venture Fund, SVP Scheer and Company, Postdoctoral Fellow, Yale University
  • Co-founder Aegerion, Tengion, Optherion and Axerion

 

 

CONTACT US

GORDON MUNRO, BSc PhD,

Principal scientist

  • Principal Scientist Hoba Therapeutics (part-time)
  • Senior scientist, Danish Headache Center
  • > 15 years pharma experience(NeuroSearch, Lundbeck) in pain drug discovery
  • Published (majority senior or first author) >60 pain and opioid-related peer-reviewed publications and 14 patents
  • Extensive experience with outsourcing to academia and CROs
  • Worked with 4 pain-related small molecules at NS and Lundbeck that progressed into humans

 

 

TEIT E. JOHANSEN, MSc, PhD

Board member

  • SVP Global Research, ALK A/S
  • Co-founder of NsGene A/S, served as President and CEO
  • Co-founder and board member Zgene A/S
  • Head of Molecular Pharmacology, Neurosearch A/S
  • Assistant professor at John Hopskins University

 

 

MORTEN GRAUGAARD DØSSING, MSc

Board member (Novo Seeds)

 

  • Director Novo Seeds
  • Member of the board of directors of Merozyne Therapeutics, NMD Pharma.
  • Previously Director Corporate Development H. Lundbec A/S, leading acquisition of Chelsea Therapeutics, and alliance agreement with Otsuka
  • Experienced in technology transfer, commercialization and establishment of bio-and medtech

 

c/o Cobis

Ole Maaløes vej 3,

DK-2200

keap@hobatherapeutics.com

Tel: +45 31101285

Hoba Therapeutics

 

Disease modifying treatments for neuropathic pain